Parents who have been told to hold off on the combined measles, mumps, and rubella shot and wait for three separate ones now have a detailed argument for why that trade-off does not work, complete with studies.
Public health scientist Jess Steier, DrPH, has published a point-by-point response in CIDRAP to a Wall Street Journal opinion piece, written by a neurologist, that argued the MMR vaccine should be separated into three shots and that the executive order recommending the same fits with the science. Her conclusion is that splitting the vaccine buys a household more injections, more visits, higher costs, and a longer stretch of incomplete protection, with nothing measured on the other side of the ledger.
Two things need stating first. This is an opinion piece rather than a new research finding, and CIDRAP notes that op-ed views are the authors' own. What makes it worth reporting is that the underlying claims can be checked against published studies and federal guidance.
What the Vaccine Is Holding Back
Steier opens with the part of the debate that tends to be skipped, which is what measles itself does. Acute encephalitis occurs in roughly one in every 1,000 measles cases and often leaves permanent damage. Subacute sclerosing panencephalitis surfaces seven to ten years after infection, dismantles a child's language and movement, and is almost always fatal. Measles also produces immune amnesia, erasing part of what a child's immune system has already learned and leaving them vulnerable again to infections they had beaten.
The push to separate the shots is not new. Andrew Wakefield recommended it in 1998, based on a study of only 12 children that was later retracted due to fraud. What the Wall Street Journal piece adds is a proposed mechanism and a set of citations, which make it checkable.
The Genetic Studies at the Center of the Argument
The scientific core of the case for splitting rests on children with variants in SCN1A, a gene that encodes a sodium channel involved in normal neuronal firing. Those children can have seizures and neurologic deterioration after vaccination, which is true and is where the argument starts.
The history runs the other way. In 2006, Berkovic and colleagues searched for SCN1A variants in children whose symptoms were described as vaccine encephalopathy. They tested 14 children and found mutations in 11, which arose de novo in those children rather than being inherited, in every case where parental DNA was available. Those children had Dravet syndrome, a severe genetic epilepsy. The vaccine had not caused it.
Four years later, the same group asked whether vaccination changed the disease course and found that it did not. Vaccination can pull a first seizure earlier in a child who was going to have one, but it does not change intellectual outcome, seizure type, or trajectory, and the authors concluded vaccination should not be withheld from these children.
Steier's practical objection concerns whom a splitting policy would protect. Dravet syndrome occurs in roughly one in 15,700 US births, and because most of these variants arise newly, there is no family history to screen for and no way to identify these infants at the twelve-month visit. For children already known to have the condition, pediatric neurologists manage the risk directly with individualized plans that may include fever reducers around vaccination and rescue medication; routine vaccination is still recommended.
The Fever Traces Back to the Measles Component
The mechanism proposed for splitting is to reduce what the Wall Street Journal piece called "peak inflammation." Steier makes two arguments against it.
The first is that the CDC attributes most adverse events after MMR, including fever, to the measles component, and a child receiving three separate shots still receives that component. Splitting does not remove the source of the fever.
The second is that peak inflammation is not a standard measure. Researchers track specific inflammatory markers, which peak at different times and levels, and Steier says nobody has measured any of them for combined MMR versus its separate components. That leaves no evidence that the combination produces a higher peak and no interval at which spacing would lower one. The CDC's MMR vaccine safety page states that no published evidence shows a benefit to splitting MMR into three shots.
She also notes that the executive order itself does not mention inflammation. The order, as published, rests on alignment with peer-developed countries, parental choice, and a Department of Health and Human Services scientific assessment completed in January, which provides the inflammatory rationale the opinion piece supplies for the policy.
Delay Is the One Variable Anyone Has Measured
The strongest empirical point in the piece concerns timing. Vaccine Safety Datalink analysis found the relative incidence of seizures after a first MMR dose was more than twice as high at 16 to 23 months as at 12 to 15 months.
That matters because splitting, by construction, pushes vaccination later. If three shots can be given at one visit, nothing about the immune exposure has changed, and the rationale disappears. If they must be spaced, a two-dose series could become as many as six vaccination encounters, and each additional encounter is a point at which a child can drop out of the series. The order pushes in that direction on its own terms: it states that, to the maximum extent feasible, all childhood immunizations should be given at separate medical visits. Steier's argument is that delay is the only element of this proposal that anyone has actually studied, and the data indicate that it makes seizures more likely rather than less likely.
The access argument follows from the same arithmetic. Coverage falls when a shift changes, a sibling gets sick, or a copay lands in a bad week, and families with the least flexibility absorb that first. Whether children return is an outcome that determines whether a vaccination policy succeeds or fails, not a scheduling detail.
A Precedent for Separating Shots When Evidence Supports It
The comparison Steier draws is to MMRV, the combined shot that also covers chickenpox. When post-licensure monitoring found it roughly doubled febrile seizure risk compared with separate MMR and varicella shots in the week or two after a first dose, the federal advisory committee issued an interim recommendation in February 2008, dropping its existing preference for MMRV, then updated the formal recommendations in June 2009 once its working group finished the analysis.
That example runs counter to the framing that the system resists separating vaccines. It separated them once, on a preliminary safety signal, because there was a measured difference to act on.
On the longer-term question, Steier cites a Danish cohort finding no increased epilepsy rate in children whose febrile seizures followed MMR compared with children whose seizures had other causes, and a fifteen-year US cohort published in January in which no child developed epilepsy after MMR receipt. Her summary of the whole exchange is blunt: "Three shots are not better than one."
For families, nothing at the pediatrician's office has changed. No single-disease measles, mumps, or rubella vaccine is licensed in the United States, and the order itself recommends the three-shot approach only once such products are domestically available. MedicalDaily previously reported that one manufacturer put the timeline at roughly a decade.
Parents whose child has a seizure disorder or a known genetic epilepsy should raise it with a pediatrician or neurologist rather than acting on an opinion column. That is where an individualized plan is made. Anyone weighing a delay should factor in current measles transmission, which the CDC tracks weekly. What remains unresolved is procedural: a federal task force is directed to deliver plans within ninety days, and the litigation that has already delayed implementation of the narrowed federal schedule is still running.
Key Questions Answered
Is this a new study or an opinion? An opinion piece by public health scientist Jess Steier, DrPH, published by CIDRAP. The studies she cites are published research, but the argument is analysis rather than a new finding.
Does splitting MMR reduce fever or seizure risk? No evidence shows that it does. The CDC states that no published evidence supports a benefit of splitting MMR, and it attributes most adverse events after MMR, including fever, to the measles component, which a separate measles shot still provides.
What about children with genetic epilepsy? Research found that vaccination can bring a first seizure forward in children with SCN1A variants but does not change the course of the disease, and the study authors concluded that vaccination should not be withheld.
Could separating the shots cause harm? The concern raised is the delay. Vaccine Safety Datalink analysis found seizure incidence after a first MMR dose was more than twice as high at 16 to 23 months as at 12 to 15 months.
Can I get separate shots now? No. No single-disease measles, mumps, or rubella vaccine is licensed in the United States, and the order applies only once such products are domestically available.
Has the recommended schedule changed? The pediatrics academy schedule still recommends two doses of the combined vaccine at 12 to 15 months and at 4 to 6 years. Ask your practice which schedule it follows.
Who should I talk to about my specific child? A pediatrician, or a pediatric neurologist if your child has a seizure disorder or known genetic epilepsy. Individualized plans exist for children at higher risk.
